anayamalik, Author at European Medical Journal - Page 56 of 128

Link Found Between Childhood Abuse and COVID Symptoms

National surveillance data has found that individuals who experienced adverse childhood events (ACEs) face significantly higher odds of developing long-term COVID symptoms.

Patient Attitudes Towards Psychedelic-Assisted Therapy: 50% Say Yes

A new survey reveals that nearly half of patients receiving radiation therapy for cancer are open to exploring psychedelic-assisted therapy, spotlighting a growing curiosity about novel approaches to managing cancer-related distress.

This University Campus Is Taking Sugar Off the Menu

A new mixed methods study from Malaysia aims to reshape the campus food environment by reducing salt and sugar in canteen offerings, with expected benefits for student and staff health.

Landmark Trial Spurs New Anal Cancer Screening Guidelines in HIV

Anal cancer screening in people with HIV (PWH) is entering a new era, following major advances in evidence and recent guideline updates that aim to reduce cancer burden in this high-risk group.

Psoriasis in Cancer: New Guidance Emerges

Immune checkpoint inhibitors (ICIs) have transformed cancer care but can trigger immune-related adverse events such as psoriasis, complicating treatment decisions.

How Long-Term Care Homes Monitor HAIs and Resistance

A national survey of Canadian long-term care homes found that most facilities are actively monitoring healthcare-associated infections (HAIs), antimicrobial-resistant organisms (AROs), and antibiotic use, though the consistency and scope of these efforts vary.

GLP-1 Drugs Linked to Lower Dementia and Stroke Risk

GLP-1 receptor agonists like semaglutide and tirzepatide are linked to significantly lower risks of dementia, ischemic stroke, and all-cause mortality in adults with type 2 diabetes and obesity, according to a large US cohort study.

Dual Vaccine Shows Strong Immune Response in Adults Over 50

A new multicomponent vaccine targeting both seasonal influenza and SARS-CoV-2 has demonstrated noninferior immunogenicity and acceptable safety in adults aged 50 years and older, according to results from a Phase III randomized trial.

New Imaging Index Forecasts Lymphoma Progression

A novel deep learning approach to body composition analysis may offer a cost-effective and clinically relevant method to predict treatment outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to findings from the LOTIS-2 trial.

How Menopause Alters Systemic Sclerosis Outcomes

Menopause status significantly shapes the clinical presentation of systemic sclerosis (SSc), according to new findings from a multicenter analysis of over 1,500 women enrolled in the SPRING-SIR registry.